Novartis To Pay $470 million To Buy Pathology Testing Company Genoptix

Jan 25, 2011 | Laboratory News, Laboratory Pathology

Cancer Testing and Molecular Diagnostics Are Main Drivers in This Transaction In a deal with implications for independent clinical pathology laboratories, pharmaceutical giant Novartis (NYSE: NVS) announced that it would acquire pathology testing company Genoptix, Inc. (NASDAQ: GXDX). Novartis will pay $470 million in cash to acquire all the shares of Genoptix. Although the total amount of $470 million to be paid for Genoptix is nearly one-half billion dollars, one financial analyst who...
;